Benefits at a Glance

LEVEL CARE HEALTH

RETIREE PLAN III

013292 RETIREE PLAN 3

RETIREE PLAN 3

Please read the important information at the end of this Benefits at a Glance.

This summary shows the Coinsurance percentage the Plan pays for various services. All payments are based on the Plan's allowance for the services performed.

Benefit	IN NETWORK	OUT OF NETWORK ¹
BENEFIT PERIOD	Calendar year*	Calendar year*
DEDUCTIBLE (EMBEDDED) ²³	1	
Individual	\$350	\$350
• Family	\$700	\$700
OUT OF POCKET MAXIMUM (EMBEDDED)45	
Individual	\$3,000	\$3,000
• Family	\$6,000	\$6,000
	Unlimited	Unlimited
PREVENTIVE SERVICES		
Preventive Services	100%	80% after deductible
 Adult Immunizations 	100%	80% after deductible
 Pediatric Immunizations 	100%	80% after deductible
OUTPATIENT MEDICAL SERVICES		
 Primary Office Visit/Consultation 	\$15 copay	80% after deductible
Specialist Office Visit/Consultation	\$15 copay	80% after deductible
Podiatry	\$15 copay	80% after deductible



Benefit	IN NETWORK	OUT OF NETWORK ¹
URGENT CARE		
Urgent Care	100%	80% after deductible
RETAIL CLINIC (MINUTE CLINIC)	100%	80% after deductible
TELEMEDICINE		
Telemedicine	\$15 copay / 100%	Not Covered
THERAPY/COUNSELING SERVICES		
 Physical Therapy 	\$15 copay	80% after deductible
Occupational Therapy	\$15 copay	80% after deductible
 Speech Therapy 	80% after deductible	80% after deductible
 Cardiac Rehabilitation 	80% after deductible	80% after deductible
 Pulmonary Therapy 	80% after deductible	80% after deductible
 Orthoptic/Pleoptic Therapy (Vision Therapy) 	80% after deductible	80% after deductible
EMERGENCY MEDICAL FACILITY		3
• Emergency Medical ⁶	\$100 copay	\$100 copay / 100%
• Non Emergency	\$100 copay	\$100 copay / 100%
AMBULANCE SERVICES		
 Emergency Ambulance 	80% after deductible	80% after deductible
 Non-Emergency Ambulance 	80% after deductible	80% after deductible
INPATIENT MEDICAL SERVICES		
 Inpatient Hospital Services 	\$250 copay / 80% no deductible	\$250 copay / 80%
 Inpatient Professional Services 	100% surgeon/Anesthesia / 80% all other services, no deductible	80% after deductible
OUTPATIENT SURGICAL PROCEDURES		
 Outpatient Surgical Procedures 	80% after deductible	80% after deductible
Short Procedure Facility	\$250 copay / 80% no deductible	\$250 copay / 80%
DIAGNOSTIC TESTING OUTPATIENT		
 Diagnostic Medical 	100%	80% after deductible
 Simple Radiology 	100%	80% after deductible
 Non-Freestanding Advanced Radiology 	\$150 copay	\$150 copay / 80% after deductible
 Freestanding Advanced Radiology 	100%	80% after deductible
 Lab and Pathology 	100%	80% after deductible
MATERNITY CARE		
 Initial Prenatal Care Visit 	100%	80% after deductible
 Subsequent Prenatal Care Visit 	100%	80% after deductible
CRANIAL PROSTHESIS - WIG/HAIRPIECE	100%	100%

Benefit	IN NETWORK	OUT OF NETWORK ¹
CHIROPRACTIC SERVICES		
• Chiropractic Services 20 Visits per year ⁷	\$15 copay	80% after deductible
ALLERGY TESTS	100%	80% after deductible
ALLERGY INJECTIONS	100%	80% after deductible
NUTRITIONAL COUNSELING	\$15 copay	80% after deductible
DIALYSIS/HEMODIALYSIS	80% after deductible	80% after deductible
PRIVATE DUTY NURSING	Not Covered	Not Covered
SKILLED NURSING FACILITY	\$250 copay / 80% no deductible	\$250 copay / 80%
HOME HEALTH CARE	80% after deductible	80% after deductible
INPATIENT HOSPICE CARE	100% after deductible	85% after deductible
HOME INFUSION THERAPY	80% after deductible	80% after deductible
DURABLE MEDICAL EQUIPMENT	80% after deductible	80% after deductible
ORTHOTICS/PROSTHETICS DEVICES	80% after deductible	80% after deductible
OUTPATIENT MENTAL NERVOUS		1
 Psychotherapy Office Visit/Consultation 	\$15 copay	80% after deductible
 Psychotherapy Visit 	80% after deductible	80% after deductible
DIABETIC SERVICES		
Diabetic Education	80% after deductible	80% after deductible
Diabetic Equipment	80% after deductible	80% after deductible
 Diabetic Supplies 	80% after deductible	80% after deductible

This summary represents only a partial listing of benefits and exclusions of the Group Health Plan described in this summary. Benefits and exclusions may be further defined by medical policy. As a result, this Group Health Plan may not cover all of your health care expenses. Read your member benefit booklet carefully for a complete listing of terms, limitations, and exclusions of the Group Health Plan. For more information about your coverage, or to get a copy of the complete terms of coverage, visit www.ibxtpa.com.

Certain services require preapproval/precertification by the health plan prior to being performed. To obtain a list of services that require authorization, please log on to www.ibxtpa.com or call the phone number that is listed on the back of your identification card.

⁴Out of pocket includes medical only.

⁶Copay waived if admitted.

⁷Service limits combined across tiers.

^{*}A calendar year benefit period begins on the first day of the calendar year and ends on the last day of the calendar year. The deductible and out-of-pocket maximum amount starts at \$0 at the beginning of each calendar year.

¹It is important to note that all percentages for out-of-network services are percentages of the Plan allowance, not the actual charge of the provider. ²The in- and out-of-network deductibles cross-apply. ³Each member contributes towards his or her own deductible. The deductible is considered met when he or she reaches the individual deductible or the family deductible is met.

⁵Each member contributes towards his or her own out-of-pocket maximum. The out-of-pocket maximum is considered met when he or she reaches the individual out-of-pocket maximum or the family out-of-pocket maximum is met.

Services that require precertification

Level Care North Atlantic precertification list effective January 1, 2023

This applies to elective, nonemergency services. Some services or supplies in this list may not be covered by your benefits plan. Please check your benefit plan documents.

Inpatient services

- Acute rehabilitation admissions
- Elective surgical and nonsurgical inpatient admissions
- Elective inpatient hospital-to-hospital transfers
- Inpatient hospice admissions
- Long term acute care (LTAC) facility admissions
- Skilled nursing facility admissions

Procedures

- Carticel (ACI), osteochondral allograft, and autograft transplantations
- Cochlear implant surgery
- Obesity surgery

Reconstructive procedures and potentially cosmetic procedures

- Blepharoplasty/blepharoptosis repair
- · Bone graft, genioplasty, and mentoplasty
- Breast: reconstruction, reduction, augmentation, mammoplasty, mastopexy, insertion and removal of breast implants
- Canthopexy/canthoplasty
- Cervicoplasty
- Chemical peels
- Dermabrasion
- Excision of subcutaneous skin and/or subcutaneous tissue
- Gender reassignment surgery
- Genetically and bioengineered skin substitutes for wound care
- Hair transplants
- Injectable dermal fillers
- Keloid removal
- Lipectomy, liposuction, or any other excess fat removal procedure
- Otoplasty
- Rhinoplasty
- Rhytidectomy
- Scar revision
- Skin closures including:
 - Skin grafts
 - Skin flaps
 - Tissue grafts
- Surgery for varicose veins, including perforators and sclerotherapy

Independence

Independence Administrators

Day rehabilitation programs

Elective (nonemergency) ground, air, and sea ambulance transportation inpatient, including hospital-to-hospital transfers (excluding ground transportation, if the transfer to the receiving facility is related to services not offered at the transferring facility)

Outpatient private-duty nursing

Interventional pain management services

- Epidural injection procedures and diagnostic selective nerve root blocks
- Paravertebral facet injection/nerve block/neurolysis
- Regional sympathetic nerve block
- Sacroiliac joint injections
- Implanted spinal cord stimulators

Home-care services

- Enteral feeding therapy (tube feeding)
- Home health care
- Home infusion therapy
- Hospice

Prosthetics/orthoses

- Custom ankle-foot orthoses
- Custom knee-ankle-foot orthoses
- Custom knee braces
- Custom limb prosthetics including accessories/components
- Repair of replacement of all prosthetics/orthoses that require precertification

Durable medical equipment (DME)

- Bone growth stimulators
- Bone-anchored (osseointegrated) hearing aids
- Continuous positive airway pressure (CPAP) device and bi-level (Bi-PAP) devices
- Dynamic adjustable and static progressive stretching devices (excludes CPMs)
- Electric, power, and motorized wheelchairs, including custom accessories
- Manual wheelchairs with the exception of those that are rented
- Negative pressure wound therapy
- Neuromuscular stimulators
- Pressure-reducing support surfaces, including:
 - Air-fluidized bed
 - Non-powered advanced pressure-reducing mattress
 - Powered air flotation bed (low air loss therapy)
 - Powered pressure-reducing mattress
- Push rim activated power assist devices
- Repair or replacement of all DME items that require precertification
- Speech-generating devices

Medical foods

Hyperbaric oxygen therapy

Proton beam therapy

Sleep studies (facility-based)

Transplants

• All transplant procedures, with the exception of corneal transplants

Mental health/serious mental illness/ substance abuse¹

- Mental health and serious mental illness treatment (inpatient/partial hospitalization programs/intensive outpatient programs)
- Repetitive transcranial magnetic stimulation (rTMS)
- Substance abuse treatment (inpatient/partial hospitalization programs/intensive outpatient programs)

Autism spectrum disorders

· Applied behavioral analysis

Genetic and genomic tests requiring precertification

The following list is a guide to the types of genetic and genomic tests that require precertification. Due to the volume of tests, it is not possible to list each test separately.

Hereditary cancer syndromes

- BRCA gene testing (breast and ovarian cancer syndrome)
- Lynch syndrome gene testing
- Familial adenomatous polyposis gene testing
- PTEN gene testing (Cowden syndrome)
- General cancer type panels (such as colon, breast, or neuroendocrine cancers)

Hereditary heart diseases

- Long QT syndrome gene testing
- Aortic dilation or aneurysm syndrome testing (includes Marfan syndrome)

Other full gene analysis testing

- Cystic fibrosis full gene sequencing and deletion/ duplication analysis
- PMP22 full gene sequencing and deletion/duplication analysis (Charcot-Marie-Tooth, hereditary neuropathy)

Tests for many genetic disorders simultaneously

- Expanded carrier screening panels (such as Carrier Status DNA Insight[®], Counsyl Family Prep Screen, Pan-Ethnic Carrier Screening)
- Hearing loss panels
- Intellectual disability panels
- Noonan spectrum disorders panels

Specialty oncology tests

- Cancer gene expression or protein signature tests (such as OncotypeDX[®], MammaPrint[®], Afirma[®], Prosigna[®], HeproDX[™])
- Tumor molecular profiling (such as FoundationOne[®], neoTYPE[™], OncoPlexDx[®], and many others)
- Tissue of origin testing (for cancer of unknown primary)
- PCA3 testing for prostate cancer

Pharmacogenomic tests

- Cytochrome P450 metabolism gene testing (CYP2D6, CYP2C9, CYP2C19)
- Specialized drug response gene panels (such as Assurex GeneSight[®], GeneTrait, Genecept[®], Millennium PGTSM)
- Warfarin response testing
- MGMT methylation analysis for glioblastoma

Other specialty tests

- Coronary artery disease risk testing (such as CorusCAD[®], CardioIQ[®], APOE, ACE, KIF6)
- Heart disease risk testing (such as CorusCAD[®], CardioIQ[®], APOE, ACE, KIF6, MTHFR)

Genome-wide tests

- Microarray studies
- Whole exome testing
- Whole genome testing
- · Mitochondrial genome or nuclear testing

ANY genetic test for more than one gene or condition (often includes words like "panel" or "comprehensive" in the name)

ANY genetic test that will be billed with a non-specific procedure code

- Billed with CPT[®] codes 81400–81408 (CPT Copyright 2016 American Medical Association. All rights reserved. CPT[®] is a registered trademark of the American Medical Association.)
- Billed with an unlisted code: 81479, 81599, 84999

Specialty drugs that require precertification

All listed brands and their generic equivalents or biosimilars require precertification. This list is subject to change.

Direct Ship Drug Program

Amyotrophic lateral sclerosis agents

- Radicava[™] (ravulizumab)
- tofersen*

Antineoplastic agents/chemotherapy

- Abraxane[®] (paclitaxel protein-bound particles)
- Adcetris[®] (brentuximab vedotin)
- Alimta[®] (pemetrexed disodium)
- Alymsys[®] (bevacizumab)
- (except for ophthalmological conditions)
- Avastin^{®‡} (bevacizumab) (except for ophthalmological conditions)
- Azedra (iobenguane I- 131)
- Blenrep[™] (belantamab mafodotin)
- Blincyto[®] (blinatumomab)
- Cyramza[®] (ramucirumab)
- Darzalex[®] (daratumumab)
- Darzalex Faspro[™] (daratumumab/hyaluronidase-fihj)
- Enhertu (fam-trastuzumab-deruxtecan-nxki)
- Erbitux[®] (cetuximab)
- Erwinaze[®] (asparaginase Erwinia chrysanthemi)
- Herceptin^{®‡} (trastuzumab)
- Herceptin Hylecta[™] (trastuzumab)
- Herzuma[®] (trastuzumab-pkrb)
- Instiladrin[®]* (nadofaragene firadenovec)
- Kadcyla[®] (ado-trastuzumab emtansinel)
- Kanjinti[™] (trastuzumab-anns)
- Kimmtrak[®] (tebentafusp-tebn)
- Kyprolis[®] (carfilzomib)
- Lumoxiti[™] (moxetumomab pasudotox-tdfk)
- Margenza[™] (margetuximab)
- mirvetuximab soravtansine*
- Monjuvi[®] (tafasitamab-cxix)
- mosunetuzumab*
- Mvasi[™] (bevacizumab- awwb) (except for ophthalmological conditions)
- Ogivri™ (trastuzumab-dkst)
- Ontruzant[®] (trastuzumab-dttb)
- Opdualag[™] (nivolumab and relatlimab-rmbw)
- oportuzumab monatox*
- Padcev[™] (enfortumab vedotin-ejfv)
- Pemfexy[™] (pemetrexed)
- Perjeta[®] (pertuzumab)
- Phesgo[™] (pertuzumab/trastuzumab/hyaluronidase-zzxf)
- Pluvicto[™]* (Lutetium Lu 177 vipivotide tetraxetan)
- Polivy[™] (polatuzumab vedotin-piiq)
- Poteligeo[™] (mogamulizumab)
- Provenge[®] (sipuleucel-T)
- Riabni (rituximab-arrx)
- Rituxan^{®‡} (rituximab)
- Rituxan Hycela[™] (rituximab/ hyaluronidase human)
- Ruxience[™] (rituximab-pvvr)

- Rybrevant (amivantamab-vmjw)
- Rylaze[™] (asparaginase Erwinia chrysanthemi [recombinant]-rywn)
- Sarclisa (isatuximab-irfc)
- SH-111*
- Taclantis* (paclitaxel injection concentrate for suspension)
- teclistamab*
- Tivdak[™] (tisotumab vedotin-tftv)
- Trazimera[™] (trastuzumab-qyyp)
- tremelimumab*
- Trodelvy[™] (sacituzumab govitecan-hziy)
- Truxima[®] (rituximab-abbs)
- Vegzelma[®] (bevacizumab-adcd) (except for ophthalmological conditions)
- Xofigo (radium Ra 223)
- Yervoy™ (ipilimumab)
- Zepzelca[™] (lurbinectedin)
- Zevalin (ibritumomab tiuxetan)
- · Zirabev (except for ophthalmological conditions)
- Zynlonta[™] (loncastuximab tesirine)

Anti-PD-1/ PD-L1 human monoclonal antibodies⁺/chemotherapy

- balstilimab*
- Bavencio[®] (avelumab)
- Imfinzi[™] (durvalumab)
- Jemperli (dostarlimab-gxly)
- Keytruda[™] (pembrolizumab)
- Libtayo[®] (cemiplimab-rwlc)
- Opdivo[®] (nivolumab)
- penpulimab*
- retifanlimab*
- sintilimab*
- Tecentriq[™] (atezolizumab)
- tislelizumab*
- toripalimab*

Bone-modifying agents

- Evenity[®] (romosozumab-aqqg)
- Prolia[®] (denosumab)
- Xgeva[®] (denosumab)

Botulinum toxin agents

• Botox[®] (onabotulinumtoxinA)

Chemotherapy-induced nausea and vomiting (CINV) agents

• Sustol[®] (granisetron extended-release for injection)

Chimeric antigen receptor (CAR-T) therapies/ chemotherapy⁺

- Abecma[™] (idecabtagene vicleucel)
- Breyanzi[®] (lisocabtagene maraleucel)
- Carvykti[™] (ciltacabtagene autoleucel)
- Kymriah[™] (tisagenlecleucel)
- Tecartus[™] (brexucabtagene autoleucel)
- Yescarta[™] (axicabtagene ciloleucel)

Endocrine/metabolic agents

- Acthar H.P.[®] (corticotropin)
- cosyntropin depot*
- Lutathera® (lutetium Lu 177 dotatate)/chemotherapy
- Makena[®] (hydroxyprogesterone caproate)
- Sandostatin[®] LAR (octreotide)/chemotherapy
- Somatuline[®] depot (lanreotide)/chemotherapy

Enzyme replacement agents*

- Aldurazyme[®] (laronidase)
- Brineura[™] (cerliponase alfa)
- Cerezyme[®] (imiglucerase)
- cipaglucosidase alfa*
- Elaprase[®] (idursulfase)
- Elelyso[®] (taliglucerase alfa)
- Fabrazyme[®] (agalsidase beta)
- Kanuma[®] (sebelipase alfa)
- Lumizyme[®] (alglucosidase alfa)
- Mepsevii[™] (vestronidase alfa-vjbk)
- Naglazyme[®] (galsulfase)
- Nexviazyme[®] (avalglucosidase alfa)
- pegunigalsidase alfa*
- Replagal[®]* (agalsidase alfa)
- Revcovi[™] (elapegademase-lvlr)
- Vimizim[™] (elosulfase alfa)
- VPRIV[®] (velaglucerase alfa)
- Xenpozyme[®] (olipudase alfa)

Gene replacement/gene editing therapy*

- beremagene geperpavec*
- etranacogene dezaparvovec*
- Luxturna[™] (voretigene neparvovec-rzyl)
- Roctavian* (valoctocogene roxaparvovec)
- Skysona[™] (elivaldogene autotemcel)
- Zolgensma[®] (onasemnogene abeparvovec-xioi)
- Zynteglo[®] (betibeglogene autotemcel)

Hemophilia/Coagulation factors*

Hyaluronate acid products

- Cingal* (triamcinolone and Monovisc)
- Durolane[®]
- Euflexxa™
- Gel-One[®]
- Gelsyn-3[™]
- GenVisc 850®
- Hyalgan[®]
- Hymovis[®]
- Supartz[®]
- Synojoynt[™]
- Triluron[™]
- TriVisc[™]
- VISCO-3[®]

Immunological agents

- Actemra[®] IV (tocilizumab)
- Avsola™ (infliximab-axxq)
- Benlysta[®] IV (belimumab)
- Entyvio[™] (vedolizumab)
- Ilumya[™] (infliximab-dyyb)
- Inflectra[™] (tildrakizumab-asmn)
- Infliximab (unbranded)
- Ixifi[™] (infliximab-gbtx)
- Orencia[®] IV (abatacept)
- Remicade^{®‡} (infliximab)
- Renflexis[™] (infliximab-abda)
- Saphnelo[™] (anifrolumab)
- Simponi[®] Aria (golimumab for infusion)
- Skyrizi[®] IV* (risankizumab-rzaa)
- Spevigo[®] (spesolimab)
- Stelara[®] IV (ustekinumab)

Intravenous Immune Globulin/Subcutaneous Immune Globulin (IVIG/SCIG)⁺

Multiple sclerosis agents*

- Lemtrada[®] (alemtuzumab)
- Ocrevus[™] (ocrelizumab)
- Tysabri[®] (natalizumab)
- ublituximab*

Neutropenia

- efbemalenograstim*
- Fulphila[™] (pegfilgrastim-jmbd)
- Fylnetra[®] (pegfilgrastim-pbbk)
- Lapelga*
- Neulasta^{®‡} (pegfilgrastim)
- Neulasta Onpro[™] (pegfilgrastim body injector kit)
- Neupogen[®] (filgrastim)
- Nivestym[™] (filgrastim-aafi)
- Nyvepria[™] (pegfilgrastim-apgf)
- plinabulin*
- Releuko[™] (filgrastim-ayow)
- Rolvedon[™] (eflapegrastim)
- Stimufend[®] (pegfilgrastim-fpgk)
- Udenyca[™] (pegfilgrastim-cbqv)
- Ziextenzo® (pegfilgrastim-bmez)

Ophthalmic agents

- abicipar*
- Beovu[®] (brolucizumab-dbll)
- Byooviz™ (ranibizumab-nuna)
- Cimerli™ (ranibizumab-eqrn)
- Eylea^{®‡} (aflibercept)
- Lucentis^{®‡} (ranibizumab)
- Susvimo[™] (ranibizumab injection, port delivery system)
- Tepezza[™] (teprotumumab-trbw)
- Vabysmo[®] (faricimab-svoa)

Pulmonary arterial hypertension*

- Flolan[®] (epoprostenol GM)
- Remodulin[®] (treprostinil)
- Revatio[®] (sildenafil)
- Trevyent[®] (treprostinil)
- Tyvaso[®] (treprostinil)
- Veletri[®] (epoprostenol AS)
- Ventavis[®] (iloprost)

Respiratory agents

- Cinqair[®] (reslizumab)
- Synagis[®] (Respiratory syncytial virus [RSV], monoclonal antibody, recombinant)
- Tezspire[™] (tezepelumab-ekko)
- Xolair[®] (omalizumab)

Respiratory enzymes (Alpha-1 antitrypsin)*

- Aralast
- Glassia™
- Prolastin[®]
- Zemaira®

Miscellaneous therapeutic agents

- Adakveo[®] (crizanlizumab-tmca)
- Ampligen[®]* (rintatolimod)
- Amvuttra™ (vutrisiran)
- Cosela[®] (trilaciclib)
- Crysvita[®] (burosumab-twza)
- donislecel*
- Enjaymo (sutimlimab-jome)
- Evkeeza[™] (evinacumab)
- Exenatide sustained-release ITCA 650*
- Gamifant[®] (emapalumab-lzsg)
- Givlaari[®] (givosiran)
- Ilaris[®] (canakinumab)
- Krystexxa[®] (pegloticase)
- Leqvio[®] (inclisiran)
- narsoplimab*
- Onpattro[™] (patisiran)
- Oxlumo[®] (lumasiran)
- Reblozyl[®] (luspatercept-aamt)
- Remune*
- Rethymic[™] (allogeneic processed thymus tissue-agdc)
- Soliris^{®‡} (eculizumab)
- Spinraza[™] (nusinersen)
- teplizumab*
- Ultomiris[™] (ravulizumab-cwvz)
- Uplizna[™] (inebilizumab)
- Vyepti[™] (eptinezumab-jjmr)
- Vyvgart[™] (efgartigimod alfa-fcab)
- Xiaflex[®]

* Pending FDA approval.

† All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.

‡ Precertification requirements apply to all FDA-approved biosimilars to this reference product.

© 2022 Independence Administrators

Independence Administrators is an independent licensee of the Blue Cross and Blue Shield Association.

